These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32545313)

  • 1. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
    Lukhwareni A; Gededzha MP; Amponsah-Dacosta E; Blackard JT; Burnett RJ; Selabe SG; Kyaw T; Mphahlele MJ
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32545313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
    Archampong TN; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Gillani FS; Yang H; Boamah I; Flanigan T; Kwara A
    BMC Infect Dis; 2016 Jan; 16():14. PubMed ID: 26759172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
    Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
    Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Archampong TN; Boyce CL; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Blackard JT; Kwara A
    Antivir Ther; 2017; 22(1):13-20. PubMed ID: 27167598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
    Jia HH; Li KW; Chen QY; Wang XY; Harrison TJ; Liang SJ; Yang QL; Wang C; Hu LP; Ren CC; Fang ZL
    Intervirology; 2018; 61(3):123-132. PubMed ID: 30368502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
    Kouanfack C; Aghokeng AF; Mondain AM; Bourgeois A; Kenfack A; Mpoudi-Ngolé E; Ducos J; Delaporte E; Laurent C
    Antivir Ther; 2012; 17(2):321-6. PubMed ID: 22290198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
    Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
    Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
    HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
    Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
    BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy.
    Weissmann L; Picone CM; Gouvêa MSG; Ferreira PRA; Viana MSVB; Pinho JRR; Cassenote AJF; Segurado AC
    Braz J Infect Dis; 2019; 23(6):441-450. PubMed ID: 31715124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
    Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
    AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
    Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T
    PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
    Aoudjane S; Chaponda M; González Del Castillo AA; O'Connor J; Noguera M; Beloukas A; Hopkins M; Khoo S; van Oosterhout JJ; Geretti AM
    Clin Infect Dis; 2014 Dec; 59(11):1618-26. PubMed ID: 25100867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
    Stockdale AJ; Phillips RO; Beloukas A; Appiah LT; Chadwick D; Bhagani S; Bonnett L; Sarfo FS; Dusheiko G; Geretti AM;
    Clin Infect Dis; 2015 Sep; 61(6):883-91. PubMed ID: 26021992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
    Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V
    J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
    Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
    J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
    Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
    Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case series of intermittent nucleoside analogue-based (NA) regimen to maintain HBV virological suppression in coinfected HBV/HIV patients with suppressed viremia.
    Seang S; Detruchis P; Todesco E; Valantin MA; Schneider L; Palich R; Peytavin G; Pourcher V; Marcelin AG; Katlama C
    Infect Dis Now; 2024 Oct; 54(7):104980. PubMed ID: 39313158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia.
    Wandeler G; Musukuma K; Zürcher S; Vinikoor MJ; Llenas-García J; Aly MM; Mulenga L; Chi BH; Ehmer J; Hobbins MA; Bolton-Moore C; Hoffmann CJ; Egger M;
    PLoS One; 2016; 11(3):e0152043. PubMed ID: 27032097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.